4-methylbenzoxazole

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并恶唑类
• 英文名称: 4-methylbenzoxazole
• 英文别名: 4-methylbenzo[d]oxazole；4-methyl-1,3-benzoxazole
• 化学式: C₈H₇NO
• 分子量: 133.15
• InChiKey: VATOOGHIVDLALN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  10
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  26
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  4-methylbenzoxazole 在 lithium hexamethyldisilazane 作用下， 以 四氢呋喃 、 乙腈 为溶剂， 反应 6.16h， 生成 2-[(4-Methyl-1,3-benzoxazol-2-yl)amino]ethanol
  参考文献：
  名称：

  A method for the synthesis of 2-aminobenzoxazoles

  摘要：

  A synthesis of 2-aminobenzoxazoles from the parent C-H compound is described. The procedure involves deprotonation at the 2-position of the benzoxazole and quenching the intermediate organolithium species with a halogen electrophile. The 2-halobenzoxazole is then treated in the same pot with an amine nucleophile to afford the desired product. The substrate scope and selectivity of the reaction are presented. The method is operationally simple and provides access to a variety of amine products bearing additional nucleophilic heteroatoms. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tetlet.2011.12.001
• 作为产物：
  描述：

  2-氨基-3-甲基苯酚 、 原甲酸三乙酯 反应 4.0h， 以75%的产率得到4-methylbenzoxazole
  参考文献：
  名称：

  苯并恶唑的银介导直接胺化：将氨基的来源从甲酰胺调整为母体胺

  摘要：

  来源：甲酰胺或母体胺被用作氨基介导的苯并恶唑的银基胺化反应。尽管与甲酰胺的反应在高温下进行，但与胺的直接胺化反应却在温和得多的条件下进行（参见方案）。光学活性的氨基也可以不消旋地安装。

  DOI：

  10.1002/anie.200903957

文献信息

• [EN] THERAPEUTIC COMPOUNDS AND COMPOSITIONS<br/>[FR] COMPOSÉS ET COMPOSITIONS THÉRAPEUTIQUES
  申请人：AGIOS PHARMACEUTICALS INC

  公开号：WO2014139325A1

  公开（公告）日：2014-09-18

  Compounds of general formula (I) and compositions comprising compounds of general formula (I) that modulate pyruvate kinase are described herein. Also described herein are methods of using the compounds that modulate pyruvate kinase in the treatment of diseases.

  本文描述了一般式（I）化合物和包含调节丙酮酸激酶的一般式（I）化合物的组合物。本文还描述了利用调节丙酮酸激酶的这些化合物治疗疾病的方法。
• Copper-Catalyzed Oxidative Amination of Benzoxazoles via C−H and C−N Bond Activation: A New Strategy for Using Tertiary Amines as Nitrogen Group Sources
  作者：Shengmei Guo、Bo Qian、Yinjun Xie、Chungu Xia、Hanmin Huang

  DOI：10.1021/ol1030298

  日期：2011.2.4

  method for oxidative amination of azoles with tertiary amines via copper-catalyzed C−H and C−N bond activation has been developed. This protocol can be performed in the absence of external base and only requires atmospheric oxygen as oxidant. The catalyst system is very simple and efficient, which opens a new way for using tertiary amines as nitrogen group sources for C−N bond formation reactions.

  通过铜催化的CH和CN键活化作用，开发了一种高效，概念上新颖的用叔胺氧化唑类胺的方法。该方案可以在不存在外部碱的情况下进行，并且仅需要大气中的氧气作为氧化剂。催化剂体系非常简单和高效，这为使用叔胺作为C-N键形成反应的氮源提供了新途径。
• Palladium-catalyzed trisallylation of benzoxazoles and 2-aryl-1,3,4-oxadiazoles with alkyne
  作者：Jun Zheng、Fereshteh Hosseini-Eshbala、Ya-Xi Dong、Bernhard Breit

  DOI：10.1039/c8cc09165j

  日期：——

  In this report, a palladium catalyzed direct trisallylation of azoles with alkyne via a novel subsequent mono C(sp²)–H allylation/olefin isomerization/y-selective double C(sp³)–H allylation process was developed. A wide range of substituted trisallylated azoles bearing all quaternary carbon centers has been synthesized efficiently and with high atom economy.

  本报告开发了一种钯催化唑类化合物与炔烃直接三烯丙基化的新工艺，该工艺采用了新型的后续单 C(sp2)-H 烯丙基化/烯烃异构化/y-选择性双 C(sp3)-H 烯丙基化工艺。我们以较高的原子经济性高效合成了一系列含有所有季碳中心的取代三烯丙基唑。
• THERAPEUTIC COMPOUNDS AND COMPOSITIONS
  申请人：Cianchetta Giovanni

  公开号：US20140288081A1

  公开（公告）日：2014-09-25

  Compounds of general formula I: and compositions comprising compounds of general formula I that modulate pyruvate kinase are described herein. Also described herein are methods of using the compounds that modulate pyruvate kinase in the treatment of diseases.

  通式I的化合物： 以及包含调节丙酮酸激酶的通式I化合物的组合物在此处被描述。此外，在此处还描述了利用调节丙酮酸激酶的化合物治疗疾病的方法。
• [EN] COMPOSITIONS AND METHODS FOR INHIBITING PROTEIN EMBRYONIC ECTODERM DEVELOPMENT ACTIVITY AND TREATING DISEASE<br/>[FR] COMPOSITIONS ET PROCÉDÉS POUR L'INHIBITION DE L'ACTIVITÉ DE DÉVELOPPEMENT D'ECTODERME EMBRYONNAIRE DE PROTÉINE ET DE TRAITEMENT D'UNE MALADIE
  申请人：EXO THERAPEUTICS INC

  公开号：WO2021195183A1

  公开（公告）日：2021-09-30

  The invention provides compounds that are inhibitors of the protein embryonic ectoderm development (EED), pharmaceutical compositions, their use in modulating the activity of EED, and their use in the treatment of medical disorders, such as cancer. The invention further provides methods of treating medical disorders, such as cancer, and covalently modifying and/or modulating the activity of EED, using an agent that reacts with, and forms a covalent bond to, cysteine324 of EED.

  这项发明提供了抑制蛋白胚胎外胚层发育（EED）的化合物，药物组合物，它们在调节EED活性中的应用，以及它们在治疗癌症等医学疾病中的应用。该发明还提供了治疗医学疾病（如癌症）的方法，并利用一种与EED的半胱氨酸324发生反应并形成共价键的试剂，对EED进行共价修饰和/或调节活性。